Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04613557 · ClinicalTrials.gov registry record · Phase 1
Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapse/Refractory Multiple Myeloma, sponsored by Celyad Oncology.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT04613557: Active Phase 1 study of Relapse/Refractory Multiple Myeloma, sponsored by Celyad Oncology.
NCT04613557 is a Phase 1 study of Relapse/Refractory Multiple Myeloma that is active but no longer recruiting, run by Celyad Oncology. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04613557, a Phase 1 study of Relapse/Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Celyad Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
Primary Outcome
Occurrence of Dose Limiting Toxicities
Conditions Studied
Interventions
- DRUG Fludara
- BIOLOGICAL CYAD-211
- DRUG Endoxan
Study Locations (5)
Other
- Universitair Ziekenhuis Antwerpen - Antwerp
- Institut Jules Bordet - Brussels
- AZ DELTA - Roeselare
Florida
- H. Lee Moffitt Cancer Center - Tampa
New York
- Nyu Langone Hospitals - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2037-02 |
| Phase | Phase 1 |
What the registry record for NCT04613557 still lists
NCT04613557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Relapse/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Fludara is the first listed.
NCT04613557 lists 5 locations in 3 states (Other, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT04613557 about?
NCT04613557 is a clinical study titled "Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma". The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
What is the current status of trial NCT04613557?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-11-16. Estimated completion is 2037-02.
What conditions does trial NCT04613557 study?
This clinical trial studies the following conditions: Relapse/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT04613557?
The interventions under investigation include: Fludara (DRUG), CYAD-211 (BIOLOGICAL), Endoxan (DRUG).
Who is sponsoring clinical trial NCT04613557?
This trial is sponsored by Celyad Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04613557 being conducted?
This trial has 5 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04613557's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI